Monopar Therapeutics announced that a Phase 2 study published in Hepatology Communications demonstrated ALXN1840 (tiomolibdate choline) significantly improves copper balance in patients with Wilson disease by increasing fecal copper excretion. The open-label trial involved nine patients and showed rapid, sustained copper mobilization, even in those with long-term prior treatment. ALXN1840 was well tolerated with no serious adverse events, reinforcing its potential as a new treatment option for this rare genetic disorder. These findings support ongoing development and regulatory efforts for ALXN1840.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
